Dr. Michel J. Tremblay is a regular researcher in the field of infectious and immune diseases at the CHU Research Center of Québec-Laval University. He is also a Professor in the Department of Microbiology-Infectiology and Immunology of the School of Medicine at Laval University, and holds the Canada Research Chair in Human Immuno-Retrovirology.

He has been Vice-Dean, Research and Graduate Studies at the Faculty of Medicine, and is currently Assistant Vice-President, Research, Creation and Innovation at Laval University. Dr. Tremblay has published over 200 articles in peer-reviewed scientific journals, and to date has received nearly $ 15 million in funding as a principal investigator and just under $ 40 million in funding as co-researcher for his research projects. Dr. Tremblay has received several awards and distinctions, including the André Dupont Award from the Clinical Research Club of Quebec and the Léo-Pariseau Award from ACFAS. Dr. Tremblay is a member of the Canadian Research Consortium on HIV Healing (CanCURE) which is funded by the Canadian Institutes of Health Research (CIHR).

His research aims to deepen our knowledge of the pathogenesis of human immunodeficiency virus (HIV) infection, the etiologic agent of Acquired Immunodeficiency Syndrome (AIDS). His research focuses on several facets of HIV infection, such as the complex interactions that occur between HIV and certain target cells of the virus (e.g., macrophages, CD4 T cells, astrocytes, etc.) and large-scale analysis of gene expression patterns following viral infection, using DNA microarrays and RNA sequencing in combination with powerful bioinformatic tools.

CHUL
2705, boulevard Laurier
RC-709
Québec, Québec
Canada G1V 4G2
+1 418-525-4444, extension 48274
+1 418-654-2715

Latest news

191 entries « ‹ 1 of 39 › »

Nazli A, Dizzell S, Zahoor MA, Ferreira VH, Kafka J, Woods MW, Ouellet M, Ashkar AA, Tremblay MJ, Bowdish DM, Kaushic C

Interferon-β induced in female genital epithelium by HIV-1 glycoprotein 120 via Toll-like-receptor 2 pathway acts to protect the mucosal barrier.

Journal Article

Cell Mol Immunol, 2018, ISSN: 1672-7681.

Abstract | Links:

Barat C, Proust A, Deshiere A, Leboeuf M, Drouin J, Tremblay MJ

Astrocytes sustain long-term productive HIV-1 infection without establishment of reactivable viral latency.

Journal Article

Glia, 2018, ISSN: 0894-1491.

Abstract | Links:

Proust A, Barat C, Leboeuf M, Drouin J, Tremblay MJ

Contrasting effect of the latency-reversing agents bryostatin-1 and JQ1 on astrocyte-mediated neuroinflammation and brain neutrophil invasion.

Journal Article

J Neuroinflammation, 14 (1), pp. 242, 2017.

Abstract | Links:

Nguyen PV, Wessels JM, Mueller K, Vahedi F, Anipindi V, Verschoor CP, Chew M, Deshiere A, Karniychuk U, Mazzulli T, Tremblay MJ, Ashkar AA, Kaushic C

Frequency of Human CD45+ Target Cells is a Key Determinant of Intravaginal HIV-1 Infection in Humanized Mice.

Journal Article

Sci Rep, 7 (1), pp. 15263, 2017, ISSN: 2045-2322.

Abstract | Links:

Lodge R, Ferreira Barbosa JA, Lombard-Vadnais F, Gilmore JC, Deshiere A, Gosselin A, Wiche Salinas TR, Bego MG, Power C, Routy JP, Ancuta P, Tremblay MJ, Cohen EA

Host MicroRNAs-221 and -222 Inhibit HIV-1 Entry in Macrophages by Targeting the CD4 Viral Receptor.

Journal Article

Cell Rep, 21 (1), pp. 141-153, 2017.

Abstract | Links:

191 entries « ‹ 1 of 39 › »

Active projects

  • Centre hospitalier universitaire de Québec - CHU de Québec-Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Chaire du recherche du Canada en immuno-rétrovirologie humaine, Subvention, Secrétariat des Chaires de recherche du Canada, Chaires de recherche du Canada - Fonctionnement, from 2015-01-01 to 2021-12-31
  • CIHR University Delegates Network - Délégué UL Marc Pouliot, Subvention, Instituts de recherche en santé du Canada, Réseau des délégués universitaires (DU), from 2013-03-01 to 2022-02-28
  • Development of a safe, effective and clinically acceptable VSV-based HIV vaccine, Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2017-04-01 to 2020-03-31
  • Effect of the gut microbiota and their generated metabolites on HIV-1 biology in CD4+ T cells., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2015-07-01 to 2018-06-30
  • HIV-1 reservoir in the CNS: mode of establishment and consequences of purging strategies on this reservoir., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2014-04-01 to 2019-03-31
  • Possible outcomes of Leishmania co-infection on HIV-1 immunopathogenesis, latency and reactivation., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2014-07-01 to 2019-06-30
  • Possible outcomes of Leishmania co-infection on HIV-1 immunopathogenesis, latency and reactivation., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2015-07-01 to 2018-06-30
  • The Canadian HIV Cure Enterprise (CanCURE), Partenariat, Instituts de recherche en santé du Canada, Subvention d'équipe: La recherche d'un remède contre le VIH, from 2014-01-01 to 2018-12-31

Recently finished projects

  • A 3-D Tissue Engineered Vaginal Wall to Investigate Mucosal HIV Infection. (fonds 0493)., Subvention, Fondation de l'Université Laval, from 2014-11-05 to 2016-11-04
  • Biochemical, cellular and molecular studies to dissect the contribution of the soluble host carbohydrate binding proteins to HIV-1 pathogenesis., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2012-01-01 to 2017-03-31
  • Centre de recherche en infectiologie, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-06-01 to 2018-04-30
  • Centre de recherche sur les interactions hôte-parasite (CRIHP), Subvention, Fonds de recherche du Québec - Nature et technologies, Regroupements stratégiques, from 2015-04-01 to 2017-03-31
  • Does infection of resting memory CD4+ T cells with ICAM-1-bearing HIV-1 modulates virus pathogenesis?, Subvention, Canadian Foundation for AIDS Research (CANFAR), Subvention de recherche (80 000 $), from 2015-09-01 to 2017-08-31
  • Heterogeneity of the macrophage lineage and its influence on HIV-1 persistence, Partenariat, Fondation Canadienne pour l'innovation (La), Fonds des leaders John-R.-Evans (FLJR), from 2016-01-01 to 2017-06-30
  • New roads taken to identify and study the biological significance of host-derived molecules incorporated in HIV-1., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2013-04-01 to 2018-03-31
  • Soutien à la recherche ( soutien au projet d'équipe IRSC-CanCURE), Subvention, Université Laval - Soutien à la recherche, from 2015-07-01 to 2017-06-30
Data provided by the Université Laval research projects registery